SCHEMBL4745996

SCHEMBL4745996

c1ccc(-c2ccc3c(c2)c(-c2cc4c5cccc6c5c(cc4c4ccccc24)-c2ccccc2-6)cc2c4ccc(-c5ccccc5)c5c4c(cc32)-c2ncccc2-5)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HSD17B10 Q99714 2/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP1 P29466 1/20 0.33
HIF1A Q16665 1/20 0.33
PIK3CA P42336 1/20 0.33
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
ALK Q9UM73 1/20 0.32
FEN1 P39748 1/20 0.32
TOP2A P11388 1/20 0.31
HTT P42858 2/20 0.30
MEN1 O00255 1/20 0.30
APAF1 O14727 1/20 0.30
NPC1 O15118 1/20 0.30
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4745874 0.97 PIK3CA (0.32) L3MBTL1ALDH1A1HSD17B10HPGDTSHR
SCHEMBL4746378 0.94 PIK3CA (0.34) ALDH1A1HSD17B10PIK3CAPTGS1PTGS2
SCHEMBL4746003 0.94 PIK3CA (0.34) L3MBTL1ALDH1A1HSD17B10PIK3CAPTGS1
SCHEMBL4746366 0.93 PIK3CA (0.35) L3MBTL1ALDH1A1HSD17B10PIK3CAPTGS1
SCHEMBL4746468 0.91 PIK3CA (0.34) ALDH1A1HSD17B10PIK3CAPTGS1PTGS2
SCHEMBL4746316 0.91 PIK3CA (0.36) L3MBTL1ALDH1A1HSD17B10PIK3CAPTGS1
SCHEMBL4746334 0.91 PIK3CA (0.36) L3MBTL1ALDH1A1HSD17B10PIK3CAPTGS1
SCHEMBL4746453 0.90 PIK3CA (0.34) ALDH1A1HSD17B10PIK3CAPTGS1PTGS2
SCHEMBL4746325 0.90 FEN1 (0.35) ALDH1A1HSD17B10PIK3CAPTGS1PTGS2
SCHEMBL4746330 0.90 FEN1 (0.35) ALDH1A1HSD17B10PIK3CAPTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 L3MBTL1 1513/4885ALDH1A1 179/4885HSD17B10 2132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.